GlassScriptPhysician profile
Stefan Sicinschi
NPI 1942663331
$3,476.41
in general payments reported to CMS, 2019-2025
20 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.89 · 2021: $86.08 · 2022: $484 · 2023: $1,797 · 2024: $432 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084 · Travel and Lodging: $763 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.89 |
| Travel and Lodging | $763.08 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,871.60 | 2022-2025 | Linq II, Corevalve Evolut R, Omniasecure Mri Surescan |
| Atricure, INC. | $266.69 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $242.09 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $232.20 | 2019-2025 | Camzyos |
| Boston Scientific Corporation | $148.15 | 2023 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.30 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.74 | 2021-2025 | Jardiance |
| Baxter Healthcare | $100.20 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $61.64 | 2024-2025 | Nexletol |
| Philips North America LLC | $55.17 | 2024 | (Ck4) Mcot, (5044) Mcot |
| Biotronik INC. | $50.49 | 2022 | |
| Amgen INC. | $48.27 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $32.42 | 2023-2025 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $26.64 | 2024 | Arcalyst |
| Pfizer INC. | $26.61 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.72 | 2023 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $19.87 | 2025 | Uptravi |
| Cardiva Medical, INC. | $19.59 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Merck Sharp & Dohme LLC | $16.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Sicinschi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.